Ionis Pharmaceuticals (IONS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- US considers new sanctions on Brazilian judge, FT reports
- Six dead in 'stampede-like' incident at India temple, ANI says
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company
November 4, 2021 7:28 AM EDTNeedham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.
The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More
